Medtronic plc MDT recently announced favorable clinical trial results from the STROKE AF trial published in the Journal of the American Medical Association (JAMA). The outcome of the trial ...

Medical device major, Medtronic plc MDT recently received the U.S. FDA 510(k) clearance for its Reveal LINQ Insertable Cardiac Monitor (ICM) with TruRhythm Detection. The device is an advanced cardiac ...

The LINQ II ICM is the first continuous, long-term cardiac monitor cleared by FDA for the pediatric patient population The LINQ II system is a small (one-third the size of a AAA battery), wireless ICM ...

AccuRhythm AI algorithms now cleared by FDA for the Reveal LINQ ICM; enhancements made to the AF algorithm for the LINQ II ICM MedTech Breakthrough, an independent market intelligence organization ...

Medtronic plc MDT recently announced the receipt of the FDA approval and the CE Mark for its LINQ II insertable cardiac monitor (“ICM”) with remote programming. Notably, ICM is a new long-term ...

BRAMPTON, ON-- Medtronic of Canada today announced it has received Health Canada license for the Reveal LINQ Insertable Cardiac Monitor (ICM), the smallest implantable cardiac monitoring device ...

DUBLIN and VANCOUVER., Medtronic plc today announced one-year results from a real-world study of patients who had a cryptogenic stroke, or stroke of unknown cause. The study found that the Reveal LINQ ...

The LINQ II ICM is the first continuous, long-term cardiac monitor cleared by FDA for the pediatric patient population DUBLIN, Sept. 20, 2022 /PRNewswire/ -- Medtronic plc (NYSE:MDT), a global leader ...